NCT05626634 2025-12-03
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
Longboard Pharmaceuticals
Phase 2 Completed
Clinical Trials
11 trialsNCT03731455 2025-07-17
WIN
Wise S.r.l.
Phase NA Completed
NCT02392078 2025-04-24
LAANTERN
Monteris Medical
Completed
NCT03489187 2022-05-04
VIVID-1
MedtronicNeuro
Completed
NCT03775694 2022-05-04
dMRI-1
Medtronic Spinal and Biologics
Completed
NCT03898791 2021-08-05
A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
Eli Lilly and Company
Phase 1 Completed
NCT03650452 2021-02-18
ELEKTRA
Takeda
Phase 2 Completed
NCT02276053 2020-06-01
VIBES
UCB Pharma
Completed
NCT03955939 2020-06-01
A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body
Eli Lilly and Company
Phase 1 Completed
NCT01236053 2017-07-06
Cancer in Patients With Gabapentin (GPRD)
GlaxoSmithKline
Completed
NCT01138124 2017-05-30
Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)
GlaxoSmithKline
Completed